StockData

NewAmsterdam Pharma vs Roivant Sciences

NAMS and ROIV side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How NAMS and ROIV compare

Roivant Sciences grew revenue faster over the last twelve months (−67.6% versus −88.9% for NewAmsterdam Pharma).

Roivant Sciences keeps more of each dollar of sales as profit, with a net margin of −3535% compared with −3644% at NewAmsterdam Pharma.

Roivant Sciences scores higher on the StockData Score (7 against 6 for NewAmsterdam Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricNAMSROIV
Size and price
Market cap–$28.0B
Share price$19.39$38.71
Change, 1 year−49.4%90.8%
Change, 5 years98.1%453%
Beta (5Y)1.570.42
Employees100721
StockData Score
Total score67 (better)
Valuation score00
Growth score00
Performance score11
Health score56 (better)
Dividend score00
Valuation
P/S–3712×
P/B–6.6×
FCF yield–−2.9%
Growth
Revenue growth (TTM)−88.9%−67.6% (better)
Revenue growth, 5Y average–−19.1%
Profitability
Operating margin−3432% (better)−7915%
Net margin−3644%−3535% (better)
FCF margin−2018% (better)−10901%
Return on equity−36.8%−6.2% (better)
Return on invested capital−1046%−407% (better)
Financial health
Debt / equity0.000.00
Current ratio9.0316.72 (better)
Altman Z-score–44.02
Piotroski F-score3 (better)2
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions–78.1%
Held by insiders22.0%13.9%
Insider net buying, 12 months−$63.0M (better)−$798M
Superinvestors holding–1
Short interest, % of float–7.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.